

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 February 2009 (19.02.2009)

PCT

(10) International Publication Number
WO 2009/023232 A1(51) International Patent Classification:
A01N 43/04 (2006.01) *A61K 31/70* (2006.01)(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner LLP,
3000 K Street NW, Suite 500, Washington, DC 20007 (US).(21) International Application Number:
PCT/US2008/009703

(22) International Filing Date: 14 August 2008 (14.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/955,939 15 August 2007 (15.08.2007) US(71) Applicant (for all designated States except US): REATA
PHARMACEUTICALS, INC. [US/US]; 2801 Gatewau
Drive, Suite 150, Irving, TX 75063-2648 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): WALLING, John
[US/US]; 6908 Parkridge Blvd. #130, Irving, TX 75063
(US). PARENT, Stephan, D. [US/US]; 2120 Cumulus
Court, W. Lafayette, IN 47906 (US). JONAITIS, David,
T. [US/US]; 225 Perrin Avenue, Lafayette, IN 47901 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: NOVEL FORMS OF CDDO METHYL ESTER

Figure 1 - Chemical structure of CDDO methyl ester



$C_{32}H_{43}NO_4$
Mol. Wt.: 505.69

(57) **Abstract:** A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can be prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

WO 2009/023232 A1